pubmed-article:17135228 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17135228 | lifeskim:mentions | umls-concept:C1522565 | lld:lifeskim |
pubmed-article:17135228 | lifeskim:mentions | umls-concept:C0020542 | lld:lifeskim |
pubmed-article:17135228 | lifeskim:mentions | umls-concept:C0277785 | lld:lifeskim |
pubmed-article:17135228 | lifeskim:mentions | umls-concept:C0039155 | lld:lifeskim |
pubmed-article:17135228 | lifeskim:mentions | umls-concept:C0754710 | lld:lifeskim |
pubmed-article:17135228 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:17135228 | pubmed:dateCreated | 2007-4-2 | lld:pubmed |
pubmed-article:17135228 | pubmed:abstractText | Right ventricular systolic dysfunction (RVSD) at baseline (pre-treatment) predicts early death in patients with pulmonary hypertension (PH). However, RVSD can only be detected reliably by prohibitively invasive or expensive techniques. N-terminal B-type natriuretic peptide concentration ([NT-proBNP]) correlates with RV function in PH; however, an [NT-proBNP] threshold that indicates RVSD in individual patients has not previously been determined. Twenty-five patients with PH (pulmonary arterial hypertension (n = 19) or chronic thromboembolic PH (n = 6)) underwent cardiovascular magnetic resonance (CMR) imaging and NT-proBNP measurement at baseline. [NT-proBNP] was correlated against RV dimensions and ejection fraction (RVEF) measured directly by CMR imaging. The ability of NT-proBNP to detect RVSD (defined as a CMR-derived RVEF >2 SDS below control values) was tested and predictors of [NT-proBNP] identified. [NT-proBNP] correlated negatively with RVEF. RVSD was present in nine out of 25 patients. An [NT-proBNP] threshold of 1,685 pg.mL(-1) was sensitive (100%) and specific (94%) in detecting RVSD. RVEF and RV mass index independently predicted [NT-proBNP]. In pulmonary hypertension, a baseline N-terminal B-type natriuretic peptide concentration of >1,685 ng.L(-1) suggests right ventricular systolic dysfunction, and thus an increased risk of early death. N-terminal B-type natriuretic peptide could prove useful as an objective, noninvasive means of identifying patients with pulmonary hypertension who have right ventricular systolic dysfunction at presentation. | lld:pubmed |
pubmed-article:17135228 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17135228 | pubmed:language | eng | lld:pubmed |
pubmed-article:17135228 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17135228 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17135228 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17135228 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17135228 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17135228 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17135228 | pubmed:month | Apr | lld:pubmed |
pubmed-article:17135228 | pubmed:issn | 0903-1936 | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:MortonJ JJJ | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:DargieH JHJ | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:PeacockA JAJ | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:FosterJ EJE | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:MartinT NTN | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:GroenningB... | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:MarkP BPB | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:BlythK GKG | lld:pubmed |
pubmed-article:17135228 | pubmed:author | pubmed-author:SteedmanTT | lld:pubmed |
pubmed-article:17135228 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17135228 | pubmed:volume | 29 | lld:pubmed |
pubmed-article:17135228 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17135228 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17135228 | pubmed:pagination | 737-44 | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:meshHeading | pubmed-meshheading:17135228... | lld:pubmed |
pubmed-article:17135228 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17135228 | pubmed:articleTitle | NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. | lld:pubmed |
pubmed-article:17135228 | pubmed:affiliation | Scottish Pulmonary Vascular Unit, University of Glasgow, Glasgow G11 6NT, UK. | lld:pubmed |
pubmed-article:17135228 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17135228 | lld:pubmed |